^
CANCER:

Colorectal Cancer





Show legend
Group by Gene:
Include preclinical:

cetuximab
EGFR inhibitor
panitumumab
S95026
0
EGFR inhibitor
erlotinib
cetuximab + panitumumab
osimertinib
gefitinib
GC-1118A
ABP 494 (cetuximab biosimilar)
bevacizumab
bevacizumab-tnjn
Krabeva (bevacizumab biosimilar)
1
VEGF-A inhibitor
bevacizumab-adcd
bevacizumab-awwb
bevacizumab-maly
Aybintio (bevacizumab biosimilar)
bevacizumab-bvzr
PD1 inhibitor
pembrolizumab
nivolumab
dostarlimab-gxly
sintilimab
tislelizumab
2
PD1 inhibitor
pucotenlimab
QL1604
toripalimab-tpzi
toripalimab-tpzi
pembrolizumab
JNJ-63723283
PDR001
regorafenib
anlotinib
3
Multi-tyrosine kinase inhibitor
cabozantinib tablet
gilteritinib
ponatinib
capecitabine
4
Thymidylate synthase inhibitor
5-fluorouracil
arfolitixorin
gimeracil / oteracil / tegafur
nivolumab + ipilimumab
5
PD1 inhibitor, CTLA4 inhibitor
pembrolizumab + ipilimumab
pembrolizumab + nivolumab + ipilimumab
XmAb717
cetuximab + sotorasib
panitumumab + adagrasib
6
KRAS G12C inhibitor, EGFR inhibitor
cetuximab + adagrasib
panitumumab + sotorasib
cetuximab + RG6330
cetuximab + D-1553
7
VEGFR-2 inhibitor
ramucirumab
rivoceranib
8
HER2 inhibitor, HER2 dimerization inhibitor
trastuzumab + pertuzumab
pertuzumab / trastuzumab / hyaluronidase-zzxf
HER2 inhibitor
9
HER2 inhibitor
trastuzumab + tucatinib
trastuzumab
tucatinib
10
VEGFR inhibitor
fruquintinib
cediranib
11
Thymidine phosphorylase inhibitor
trifluridine / tipiracil
12
DNA synthesis inhibitor, DNA cross linking agent
oxaliplatin
13
Thymidylate synthase inhibitor, Topoisomerase I inhibitor
5-fluorouracil + irinotecan
capecitabine + irinotecan
14
Topoisomerase I inhibitor
irinotecan
15
Folate analog
leucovorin calcium
PD-L1 inhibitor
avelumab
16
PD-L1 inhibitor
durvalumab
envafolimab
INCB86550
CCX559
17
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
18
EGFR antagonist
SCT200
CPGJ-602
trametinib
binimetinib
19
MEK inhibitor
selumetinib
PD-0325901
IMM-6-415
20
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
FORE-8394
D-1553
adagrasib
sotorasib
21
KRAS G12C inhibitor
GFH925
RG6330
ZG19018
APG-1842
PARP inhibitor
olaparib
22
PARP inhibitor
niraparib
talazoparib
rucaparib
23
PD-L1 inhibitor, EGFR inhibitor
cetuximab + avelumab
24
PLK1 inhibitor, VEGF-A inhibitor
bevacizumab + PCM-075
25
XPO1 inhibitor
selinexor
CBS9106
26
GUCY2C-targeted CAR-T immunotherapy
GCC19CART
IM96 CAR-T cells
27
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
28
WEE1 inhibitor
AZD1775
29
SLC6A8 inhibitor
RGX-202
bevacizumab + cetuximab
30
VEGF-A inhibitor, EGFR inhibitor
bevacizumab + panitumumab
bevacizumab + erlotinib
31
DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
cisplatin + albumin-bound paclitaxel
ASN007
32
ERK2 inhibitor, ERK1 inhibitor
LY3214996
JSI-1187
33
PTPN11 inhibitor, MEK1 inhibitor
cobimetinib + RMC-4630
34
EGFR inhibitor, Multi-tyrosine kinase inhibitor
panitumumab + cabozantinib tablet
35
PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab + regorafenib
bevacizumab + sintilimab
36
VEGF-A inhibitor, PD1 inhibitor
nivolumab + bevacizumab
pembrolizumab + bevacizumab
bevacizumab + toripalimab-tpzi
37
HER2-targeted antibody-drug conjugate, Tubulin inhibitor
A166
38
FGFR inhibitor
Debio 1347
pralsetinib
39
RET inhibitor
selpercatinib
FHND5071
M6620
40
ATR inhibitor
AZD6738
SC0245
41
EGFR inhibitor, PARP inhibitor
cetuximab + olaparib
panitumumab + niraparib
cetuximab + tislelizumab
42
PD1 inhibitor, EGFR inhibitor
pembrolizumab + cetuximab
cetuximab + camrelizumab
ceritinib
43
ALK inhibitor
crizotinib + alectinib
crizotinib
BRAF inhibitor
dabrafenib
44
BRAF inhibitor
PLX4720
ABM-1310
GDC 0879
cetuximab + selumetinib
45
MEK inhibitor, EGFR inhibitor
trametinib + panitumumab
cetuximab + trametinib
46
CTLA4 inhibitor
ipilimumab
47
DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
5-fluorouracil + oxaliplatin
capecitabine + oxaliplatin
48
NKG2DL-targeted CAR-T immunotherapy
CYAD-101
49
DNA synthesis inhibitor, PARP inhibitor
olaparib + temozolomide
temozolomide
50
DNA synthesis inhibitor
cisplatin
mitomycin
gemcitabine
51
pan-RAF inhibitor, MEK1 inhibitor
cobimetinib + RG6185
52
VEGFR inhibitor, PD1 inhibitor
sintilimab + fruquintinib
fruquintinib + geptanolimab
53
PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
durvalumab + cabozantinib tablet
54
KDM4 inhibitor
TACH101
55
KRAS G12D inhibitor
MRTX1133
KS-58
56
Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
MRG003
HTI-1511
57
KRAS G12D degrader
ASP3082
58
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
59
XPO1 inhibitor, Nuclear export inhibitor
KPT-8602
60
ALK inhibitor, BRAF inhibitor, BRAF V600E inhibitor
crizotinib + vemurafenib
61
VEGF-A inhibitor, SLC6A8 inhibitor
bevacizumab + RGX-202
62
AMPK activator, Topoisomerase I inhibitor
irinotecan + metformin
63
CEA-targeted CAR-T immunotherapy
A2B530
64
EGFR inhibitor, Chemotherapy
FOLFIRI + cetuximab
CAPOX
FOLFOX
FOLFIRI
mFOLFOX7
IROX
mFOLFOX6
VIC
65
Chemotherapy
FOLFOXIRI
FOLFIRINOX
SIRB
SOXIRI
FLOX
FOLFIRINOX + mFOLFOX6
CAPIRI
BEV + CAPOX
66
Immunotherapy
Immunotherapy
PI3K inhibitor
67
PI3K inhibitor
AN2025
KU-0060648
MEN1611
68
Immunotherapy, PLK1 inhibitor
Immunotherapy + PLK1 inhibitor
69
HMG-CoA reductase inhibitor
HMG-CoA reductase inhibitor
70
PTPN11 inhibitor, ERK inhibitor
PTPN11 inhibitor + ERK inhibitor
71
T-lymphocyte cell therapy
T-lymphocyte cell therapy
CDK9 inhibitor
72
CDK9 inhibitor
ME-522
KB-0742
73
PD-L1 inhibitor, PD-L2 inhibitor
PD-L1 inhibitor + PD-L2 inhibitor
74
VEGFR inhibitor, EGFR inhibitor
EGFR inhibitor + VEGFR inhibitor
75
VEGF inhibitor
VEGF inhibitor
76
pan-RAF inhibitor, MEK inhibitor
MEK inhibitor + pan-RAF inhibitor
selumetinib + AZ 628
77
Immunotherapy, PD1 inhibitor
PD1 inhibitor + Immunotherapy
78
EGFR inhibitor, VEGF inhibitor
EGFR inhibitor + VEGF inhibitor
79
HER2-targeted CAR-T immunotherapy
HER2-targeted CAR-T immunotherapy
80
Angiogenesis inhibitor
Angiogenesis inhibitor
81
BRAF inhibitor, EGFR inhibitor
EGFR inhibitor + BRAF inhibitor
dabrafenib + panitumumab
82
VEGF-A inhibitor, Chemotherapy
CAPIRI + bevacizumab
83
PORCN inhibitor
PORCN inhibitor
84
PD-L1 inhibitor, PD1 inhibitor
PD1 inhibitor + PD-L1 inhibitor
85
MAPK inhibitor
MAPK inhibitor
86
mTOR inhibitor
mTOR inhibitor
everolimus
87
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
fam-trastuzumab deruxtecan-nxki
SHR-A1811
88
HER2 inhibitor, EGFR inhibitor
trastuzumab + lapatinib
lapatinib
89
VEGF-A inhibitor, VEGF-B inhibitor, PIGF inhibitor, Chemotherapy
FOLFIRI + ziv-aflibercept IV
90
VEGF-A inhibitor, VEGF-B inhibitor, PIGF inhibitor
ziv-aflibercept IV
91
cRAF inhibitor, BRAF inhibitor, EGFR inhibitor
panitumumab + encorafenib
cetuximab + encorafenib
92
MEK inhibitor, BRAF inhibitor, EGFR inhibitor
trametinib + dabrafenib + panitumumab
cetuximab + trametinib + dabrafenib
93
Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + leucovorin calcium
94
HMG-CoA reductase inhibitor, DNA synthesis inhibitor, DNA cross linking agent
HMG-CoA reductase inhibitor + oxaliplatin
95
DNA synthesis inhibitor, DNA cross linking agent, Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + oxaliplatin + leucovorin calcium
96
PD-L1 inhibitor, MEK1 inhibitor
atezolizumab + cobimetinib
97
PD1 inhibitor, CTLA4 antagonist
AGEN2034 + AGEN1181
98
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
cetuximab + vemurafenib
99
BRAF inhibitor, EGFR inhibitor, BRAF V600E inhibitor
vemurafenib + panitumumab
erlotinib + vemurafenib
afatinib
pyrotinib
100
HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
trastuzumab + pyrotinib
neratinib
trastuzumab + neratinib
101
XPO1 inhibitor, PD1 inhibitor
pembrolizumab + selinexor
102
PD1 inhibitor, MEK2 inhibitor, MEK1 inhibitor
camrelizumab + SHR7390
103
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib
104
VEGF-A inhibitor, Thymidylate synthase inhibitor
bevacizumab + gimeracil / oteracil / tegafur
105
TGFβ inhibitor, PD-L1 inhibitor
M7824
106
PD-L1 inhibitor, CTLA4 inhibitor
durvalumab + tremelimumab
107
cRAF inhibitor, MEK inhibitor, BRAF inhibitor, EGFR inhibitor
cetuximab + binimetinib + encorafenib
panitumumab + VS-6766
108
PIK3CA inhibitor, cRAF inhibitor, BRAF inhibitor, EGFR inhibitor
cetuximab + alpelisib + encorafenib
109
cRAF inhibitor, BRAF inhibitor
encorafenib
110
HSP90 inhibitor, PD1 inhibitor
nivolumab + pimitespib
111
c-MET-targeted antibody-drug conjugate, Topoisomerase I inhibitor
ABBV-400
HRA00129-C004
112
MEK inhibitor, BRAF inhibitor, EGFR inhibitor, BRAF V600E inhibitor
cetuximab + trametinib + vemurafenib
113
HER2 inhibitor, PD1 inhibitor, LAG-3 inhibitor
margetuximab + MGD013
114
VEGF-A inhibitor, mTOR inhibitor, EGFR inhibitor
bevacizumab + cetuximab + temsirolimus
115
CEACAM5-targeted antibody-drug conjugate, Microtubule inhibitor
SAR408701
116
cRAF inhibitor, MEK inhibitor, BRAF inhibitor
binimetinib + encorafenib
117
ERK2 inhibitor, cRAF inhibitor, BRAF inhibitor, ERK1 inhibitor, EGFR inhibitor
cetuximab + encorafenib + BVD-523
cetuximab + encorafenib + ASN007
118
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
pembrolizumab + lenvatinib
119
CD137 agonist, HER2 inhibitor
PRS-343
120
VEGF-A inhibitor, Thymidine phosphorylase inhibitor
bevacizumab + trifluridine / tipiracil
121
PD-L1 inhibitor, Immunostimulant
atezolizumab + RG6180
122
PDGFR β inhibitor, PDGFR α inhibitor, FLT3 inhibitor
ARO-002
123
cRAF inhibitor, PTPN11 inhibitor, BRAF inhibitor, EGFR inhibitor
cetuximab + encorafenib + PF-07284892
124
pan-RAF inhibitor, Src kinase inhibitor
BAL3833
125
EGFR inhibitor, MUC1 inhibitor
gatipotuzumab + tomuzotuximab
126
PD1 inhibitor, MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib + PDR001
127
CDK4 inhibitor, MEK inhibitor, CDK6 inhibitor
palbociclib + binimetinib
trametinib + palbociclib
128
pan-RAF inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + panitumumab
cetuximab + sorafenib
129
cRAF inhibitor, PD1 inhibitor, BRAF inhibitor, EGFR inhibitor
nivolumab + cetuximab + encorafenib
130
HER2 inhibitor, HER4 inhibitor, CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
pyrotinib + dalpiciclib
palbociclib + neratinib
131
HER3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
U3-1402
132
HER2-targeted antibody-drug conjugate, Microtubule inhibitor
ado-trastuzumab emtansine
JNJ-0683
133
PD-L1 inhibitor, VEGF-A inhibitor
bevacizumab + atezolizumab
134
BRAF inhibitor, BRAF V600E inhibitor, Cytochrome P450 inhibitor
FORE-8394 + cobicistat
135
c-MET inhibitor, CSF-1R inhibitor, Src kinase inhibitor
TPX-0022
136
VEGF-A inhibitor, mTORC1 inhibitor
bevacizumab + nanoparticle albumin-bound rapamycin
137
BRAF inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
vemurafenib + cobimetinib
138
CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
cetuximab + palbociclib
139
KRAS G12C inhibitor, MEK inhibitor
MEK inhibitor + sotorasib
trametinib + sotorasib
140
MEK inhibitor, BRAF inhibitor, MEK2 inhibitor, MEK1 inhibitor, BRAF V600E inhibitor
vemurafenib + HL-085
141
PD1 inhibitor, BRAF inhibitor, EGFR inhibitor, BRAF V600E inhibitor
cetuximab + vemurafenib + camrelizumab
142
HER2-targeted antibody-drug conjugate, Microtubule inhibitor, HER2 dimerization inhibitor
pertuzumab + ado-trastuzumab emtansine
143
RET inhibitor, CS-1 inhibitor, BRAF inhibitor
RXDX-105
144
DDX5 degrader
FL118
145
Bcr-abl tyrosine kinase inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
cetuximab + dasatinib
146
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
147
Notch inhibitor
PF‐06293622
148
FGFR1 inhibitor, VEGFR-2 inhibitor, EGFR inhibitor
cetuximab + BMS-582664
149
ERK inhibitor
DEL-22379
150
MEK2 inhibitor, MEK1 inhibitor
REC-4881
151
pan-RAF inhibitor
AZ 628
LY3009120
152
pan-RAF inhibitor, RIPK3 inhibitor, RIPK1 inhibitor
TAK‐632
153
pan-RAF inhibitor, RIPK3 inhibitor, RIPK1 inhibitor, BRAF inhibitor
PLX4720 + TAK‐632
154
pan-RAF inhibitor, EGFR inhibitor
cetuximab + LY3009120
155
KRAS G12D inhibitor, EGFR inhibitor
cetuximab + MRTX1133
156
mTOR inhibitor, Multi-tyrosine kinase inhibitor
everolimus + pazopanib
157
IGF-1R inhibitor
BMS-754807
158
TNKS inhibitor, CDK4 inhibitor, CDK6 inhibitor
palbociclib + MSC2504877
CS-1018
159
STING agonist
CS-1010
CS-1020
160
Trk inhibitor
FCN-098
161
TLR5 agonist, CD133-targeted CAR-T immunotherapy, Apoptosis inhibitor
CD133-specific CAR-T cell therapy + STAT-600
162
VEGFR-2 inhibitor, c-KIT inhibitor
OSI-930
163
DNA replication inhibitor, EGFR-targeted antibody-drug conjugate
ABBV-321
164
PIM inhibitor
AZD1208
165
BCAT1 inhibitor
ERG 245
166
LAMP1-targeted antibody-drug conjugate, Microtubule inhibitor
SAR428926
167
VEGFR-2 inhibitor, c-MET inhibitor, EPH receptor inhibitor, RON inhibitor, c-KIT inhibitor, Angiogenesis inhibitor
E7050
168
TrkA receptor inhibitor
GW441756
169
PTP-1B inhibitor
claramine
170
PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384
171
KRAS G12C inhibitor, cRAF inhibitor, MEK inhibitor, BRAF inhibitor
sotorasib + adagrasib + VS-6766
172
ROS1 inhibitor, Trk inhibitor, MEK inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor
trametinib + repotrectinib
173
HER2 inhibitor, Cytotoxic T lymphocyte stimulant, CD3 agonist
SAR446309
174
Microtubule stabilizer, Tubulin polymerization promoter, Sortilin inhibitor
TH 1902
175
CD122 agonist, IL-2 stimulant
NKTR-214
176
KRAS G12C inhibitor, MEK inhibitor, EGFR inhibitor
trametinib + panitumumab + sotorasib
177
PRMT5 inhibitor
MRTX9768
EPZ015666
178
AMHR2 antagonist
GM102
179
Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
dasatinib
180
E3 ubiquitin-ligase hakai inhibitor
Hakin-1
181
Tubulin polymerization promoter, Bcl2 inhibitor
paclitaxel
182
PIK3CA inhibitor, CDK4 inhibitor, CDK6 inhibitor
alpelisib + ribociclib
etoposide IV
mitoxantrone
183
Topoisomerase II inhibitor
teniposide
epirubicin
doxorubicin hydrochloride
184
ADAM9-targeted antibody-drug conjugate, Microtubule inhibitor
IMGC936
185
PD-L1 inhibitor, IL-15R stimulant
SAR445710
186
Bcl-xL degrader, KRAS G12C inhibitor
sotorasib + DT2216
187
Chk1 inhibitor
LY 2603618
188
Microtubule stabilizer, Tubulin polymerization promoter
docetaxel
189
pan-RAF inhibitor, RAS inhibitor
JZP815
190
CD137 agonist, PD1 inhibitor
Opal
191
ERK2 inhibitor, CDK4 inhibitor, ERK1 inhibitor, CDK6 inhibitor
palbociclib + ASN007
192
Menin-MLL inhibitor
BMF-219
193
ERK2 inhibitor, PTPN11 inhibitor, ERK1 inhibitor
ASN007 + ERAS-601
194
HER3 inhibitor
MM-121
195
KRAS G12C inhibitor, MEK2 inhibitor, MEK1 inhibitor
sotorasib + IMM-1-104
196
c-MET inhibitor, RON inhibitor, TrkA receptor inhibitor, Aurora kinase A inhibitor, FLT3 inhibitor
KRC-108
197
ATR inhibitor, DNA topoisomerase inhibitor
M6620 + SNB-101
198
DNA topoisomerase inhibitor
SNB-101
199
β-catenin antagonist
ST316
200
HDAC inhibitor, MEK inhibitor
binimetinib + OKI-179
201
HDAC inhibitor, cRAF inhibitor, BRAF inhibitor
encorafenib + OKI-179
202
EGFR antagonist, LGR5 inhibitor
MCLA-158
203
MEK inhibitor, MDM2 inhibitor
selumetinib + KRT-232
204
TNKS inhibitor
STP1002
G007-LK
205
BET inhibitor, MEK inhibitor
BI 894999 + LNP3794
206
TEAD1 inhibitor
IK-930
207
AMPK activator, Selective serotonin reuptake inhibitor
metformin + fluoxetine
208
Topoisomerase II inhibitor, DNA cross linking agent
idarubicin hydrochloride
209
Topoisomerase II inhibitor, DNA intercalator
daunorubicin
210
DNA synthesis inhibitor, PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab + temozolomide
211
CLDN18.2-targeted antibody-drug conjugate, DNA replication inhibitor
SOT102
212
Cripto-targeted antibody-drug conjugate, Microtubule inhibitor
BIIB015
213
Ionizing radiation emitter, CD37 inhibitor
177Lu-satetraxetan-lilotomab
214
HER3 inhibitor, α radiation emission
Ac-225 ErbB3 targeted radiotherapy
215
PARP1 inhibitor
AZD5305
216
KRAS G12C inhibitor, ERK2 inhibitor, ERK1 inhibitor
sotorasib + JSI-1187
217
VEGFR inhibitor, PDGFR inhibitor, P-glycoprotein inhibitor, c-KIT inhibitor
sunitinib + GF120918
218
TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
DS-1062a
219
PD-L1 inhibitor, CD47 inhibitor
NI-2901
220
EPCAM inhibitor, CD47 inhibitor
VBI-003
221
CDK4 inhibitor, CDK6 inhibitor
ribociclib
222
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor, WEE1 inhibitor
fam-trastuzumab deruxtecan-nxki + AZD1775
223
pan-RAF inhibitor, Angiogenesis inhibitor
SJ-C1044
224
EGFR-targeted antibody-drug conjugate
SHR-A1307
225
HSP90 inhibitor, mTOR inhibitor
sirolimus + IPI-504
226
β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
eribulin mesylate
227
PI3K inhibitor, mTOR inhibitor
RTB101
228
PLK1 inhibitor, PI3K inhibitor, RAS antagonist
rigosertib
229
eIF4A1 inhibitor
eFT226
230
MEK inhibitor, PI3K inhibitor, mTOR inhibitor
selumetinib + RTB101
231
PKC inhibitor
IDE196
232
Sortilin inhibitor
TH1901
233
Bcr-abl tyrosine kinase inhibitor, MEK inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
trametinib + dasatinib
234
SOS1 inhibitor, MEK inhibitor, pan-KRAS inhibitor
trametinib + BI 1701963
235
SIRT2 inhibitor
AGK2
236
PI3K inhibitor, FAK inhibitor, AKT inhibitor
LY294002
237
DNA replication inhibitor, CD25-targeted antibody-drug conjugate
ADCT-301
238
VEGF-A inhibitor, PARP inhibitor
bevacizumab + olaparib
239
VEGF-A inhibitor, BRAF inhibitor, BRAF V600E inhibitor
bevacizumab + vemurafenib
240
PI3K inhibitor, mTOR inhibitor, EGFR inhibitor
RTB101 + GC-1118A
241
MEK inhibitor, BRAF inhibitor, BRAF V600E inhibitor
vemurafenib + selumetinib
242
BRAF inhibitor, BRAF V600E inhibitor, AKT inhibitor
vemurafenib + MK-2206
243
THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
pemetrexed
244
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
methotrexate
245
RIPK1 inhibitor, PERK inhibitor
GSK2606414
246
CDK7 inhibitor
SY-5609
247
mTOR inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor
ABT 263 + AZD8055
248
TAK1 inhibitor
NG25
249
MEK inhibitor, PI3K inhibitor, mTOR inhibitor, mTORC1 inhibitor, mTORC2 inhibitor
PF-05212384 + PD-0325901
250
MCL1 inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor
APG1244 + MCL1 inhibitor
251
SOS1 inhibitor, MEK inhibitor
BI-3406 + MEK inhibitor
252
Bcl2 inhibitor, Bcl-xL inhibitor
APG1244
No biomarker
KRAS G12C
KRAS mutation
KRAS G12D
KRAS G12V
KRAS wild-type
KRAS A59T
KRAS exon 2 mutation
KRAS G13D
KRAS G13
KRAS exon 2 wild-type
KRAS G61H + KRAS G12A
MSI-H/dMMR + KRAS G12D
KRAS G61
KRAS A59
KRAS Q61
KRAS G12S
KRAS K117
KRAS G60D
KRAS G12
KRAS exon 3 mutation
KRAS exon 4 mutation
KRAS amplification
KRAS Q61H
KRAS A146
KRAS exon 12 mutation
KRAS exon 13 mutation
KRAS Q22X
KRAS N116T
KRAS N116H
KRAS G12R
KRAS G12A
KRAS S89P
KRAS amplification + BRAF wild-type
KRAS amplification + RAS wild-type
KRAS A146T
KRAS Q61L
BRAF V600E
BRAF V600
BRAF mutation
BRAF wild-type
RAS wild-type + BRAF wild-type
BRAF G466V
BRAF D594G
BRAF V600G
BRAF V600E + MSI-H/dMMR
BRAF mutation + MSI-L/dMMR
MSI-H/dMMR + BRAF V600E
BRAF D549G
BRAF G466A
BRAF G469A
HER-2 amplification
HER-2 positive
HER-2 expression
HER-2 mutation
HER-2 overexpression
HER-2 S310F
HER-2 R784G
HER-2 L726I
HER-2 L755S
HER-2 underexpression
HER-2 V842I
HER-2 V777L
HER-2 L866M
HER-2 S310Y
HER-2 G776S
HER-2 S310F + HER-2 amplification
HER-2 amplification + RAS wild-type
MSI-H/dMMR
MSI-L/dMMR
HER-2 amplification + RAS wild-type + BRAF wild-type
BRAF wild-type + HER-2 positive
HER-2 amplification + BRAF wild-type
NRAS wild-type
NRAS Q61
NRAS exon 4 mutation
NRAS exon 2 mutation
NRAS mutation
NRAS exon 3 mutation
NRAS amplification
NRAS overexpression
NRAS A59
NRAS H117
NRAS A146
NRAS G12
NRAS G13
NRAS G115Efs*46
PD-L1 expression
PD-L1 expression + MSI-L/dMMR
PD-L1 overexpression
TMB-H + PD-L1 expression
PD-L1 underexpression
PD-L1 elevation
PD-L1 negative
UGT1A1∗1
ERBB3 overexpression
EGFR expression
POLE V411L
POLE mutation
POLE EDM
EGFR R521K
ERBB3 expression
POLE P286R
ERBB3 underexpression
POLE A456P
EGFR S492R
EGFR overexpression
UGT1A1*1*1
UGT1A1*28
MSI-H/dMMR + POLE P286R
UGT1A1 mutation
EGFR T790M + EGFR L861Q
ERBB3 mutation
EGFR P596L
EGFR G465R
EGFR G63R
EGFR E114K
EGFR underexpression
EGFR R165Q
EGFR G724S
EGFR G719S
EGFR R222C
EGFR mutation
EGFR E709K
EGFR amplification
EGFR L858R
EGFR K467T
EGFR R451C
UGT1A1 rs1113193
EGFR K708R
RAS wild-type
PTEN mutation
BRCA1 expression
BRCA1 mutation
PTEN deletion
PTEN positive
PTEN expression
VEGFD elevation
VEGFD-L
AREG overexpression
DNMT1 rs2228611
B2M rs1901531
GPX4 rs4807542
TXN2 rs4821494
CTNNB1 mutation
FLT1 rs9582036
RSPO2 rs555008
TET3 rs7560688
KRAS A146 + TMB-H
IDH1 rs1437410
AKT1 mutation
CRY1 rs1056560
miR-31-5p underexpression
EREG overexpression
DNMT3A rs11681717
TMB-H
ATM mutation
TMB-L
RNF43 mutation + MSI-H/dMMR
RNF43 mutation
ATM deletion
RNF43 expression
RNF43 G659fs
DNMT3A mutation
AKT1 E17K
AREG expression
FLT1 amplification
RNF43 659
BRAF V600E + RNF43 mutation
TP53 mutation
RAS wild-type + HER-2 positive
NTRK3 fusion
RET fusion
CAD-ALK fusion
MTHFR C677T
IRS2 mutation
ALK fusion
NF1 mutation
PPP1R15A R251P
KMT2C mutation + TMB-H
BRAF V600E + MSI-H
IGF1 rs2946834
MSI-L/dMMR + KRAS G12V
POMK‐NRG1 fusion + KRAS G12D
POLE P286R + TMB-H
KDR V297L
MSI-H/dMMR + TMB-H + POLE mutation
NRAS mutation + BRAF mutation
PMS2 mutation + MLH1 mutation
MLL3 mutation + TMB-H
IGF1 rs6220
NF1 overexpression
MLH1 deletion+ PMS2 deletion
MGMT underexpression
NRAS G12C + BRAF V600E + BRAF V600D
KDR R961W
IRS2 amplification
POMK-NRG1 fusion + KRAS mutation
CD73 overexpression
CD73 expression
PPP1R15A K277E
MSI-H/dMMR + KRAS Mutation
MSI-H/dMMR + BRAF Mutation
ALK R1209Q
TAP2 rs1044043
TAP2 rs1800454
MGMT deletion
TP53 deletion
NRAS G12C + BRAF mutation
MGMT expression
RAS wild-type + HER-2 overexpression
IRS2 T1156M
MGMT promoter methylation
RAS wild-type + HER-2 amplification
TP53 R175H
HER-2 overexpression + RAS wild-type
KRAS wild-type + NRAS wild-type + MSI-H/dMMR
AFP elevation
PIK3CA wild-type
TET1 mutation
B2M mutation + MSI-H/dMMR
JAK2 mutation + MSI-H/dMMR
JAK1 mutation + MSI-H/dMMR
MICA-L
EZH2 underexpression
RUNX3 overexpression
TA-MUC1 elevation + EGFR expression
miR-143-3p overexpression
TSPAN6 positive
MSI-H/dMMR + POLE mutation
FAT1 mutation
FAT4 mutation
EPHB1 mutation
CCR5 expression
PlGF-L
HRD
VEGFA +405GG genotype
MSI-H/dMMR + NTRK1 fusion
PTGS2 expression
CD177 expression
KRAS mutation + PIK3CA wild-type
MSI-H/dMMR + NTRK2 fusion
MSH6 T1219I
KIR2DS4 mutation + KRAS mutation
MSI-H/dMMR + NTRK3 fusion
ANGPT2 elevation
HER-2 amplification + KRAS exon 2 wild-type
MSI-H/dMMR + TMB-H
BRCA2 mutation
KRAS mutation + YKL-40 overexpression
TAGLN expression
BGN expression
AEBP1 expression
CEACAM5 underexpression + MSI-H/dMMR
THBS2-L
MSI-H/dMMR + CD74 overexpression
MSI-H/dMMR + HLA-DQA1 overexpression
MSI-H/dMMR + HLA-DPA1 overexpression
MSI-H/dMMR + HLA-DQB1 overexpression
MSI-H/dMMR + HLA-B overexpression
MSI-H/dMMR + HLA-DRB1 overexpression
EREG overexpression + AREG overexpression
MSI-H/dMMR + RAS mutation
RAS wild-type + BRAF wild-type + HER-2 positive
TYMS underexpression
MSH2 deletion + MSH6 deletion
NTRK1 fusion
NTRK2 fusion
TAP1 rs1135216
HLA-DPB1 rs3097671
HLA-DRA rs7192
HLA-B rs2770
CIITA rs4774
HLA-G rs1610696
ERAP1 rs26653
CIP2A rs13069780
TIMELESS P1018L
miR-18a overexpression
GUCY2C expression
PD-1 overexpression
MUTYH Y179C + MUTYH G396D
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M
APC mutation + KRAS mutation
KMT2C mutation
NTRK1-TP53 fusion
KMT2D mutation
OSBPL1A overexpression
FLT3 amplification
BRAF mutation + MET amplification
RPA2 rs7356
HK2 overexpression
FBXW7 R222X
RAF1 R256S
IRF2 overexpression
PMS2 negative
GOPC-ROS1 fusion
ABCC3 overexpression
EGFR-SEPTIN14 fusion + EGFR amplification
KRAS mutation + ATM mutation
FGFR2 fusion
KRAS G12D + HER-2 amplification + TMB-H
BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR
TERT mutation + ERBB4 mutation
EXOC4-BRAF fusion
PVT1 rs2278176
ALDH2 underexpression
FGFR2-INA fusion
MSH2 489_494deTGGGTA
KRAS mutation + PD-L1 expression
MET amplification + TP53 mutation + SMAD4 mutation + CTNNA1 mutation
VCAN mutation
MSI-H/dMMR + KRAS wild-type + BRAF wild-type
VEGFA expression + FLT1 expression + KDR expression
SMAD4 mutation
IFNG expression
LINS1 I29V
ISX S28G
DFNB31 V400A
ANXA11 R230C
MET amplification
CCDC6-RET fusion
EPHA2 underexpression
IGF2 overexpression
PDGFA overexpression
VCAM1 overexpression
SPP1 elevation
miR-125b-5p overexpression
miR-17 underexpression
Let-7c overexpression
DICER1 overexpression
KMT2D mutation + TMB-H
BRIP1 mutation
RAD50 mutation
ATR mutation
INHBA rs2237432
PDGFRB overexpression
CREBBP mutation
NOTCH3 mutation
PTCH1 mutation
SPEN mutation
CIC mutation
NT5C mutation
miR-21 underexpression
CDX-2 overexpression
LYZ expression
CCND1 P241P
EGF rs444903
CXCR2 rs2230054
HIF1A P582S
CXCR1 S276T
MSI-H + HER-2 amplification
FASN A1089A
PPARG H449H
ERBB3 expression + CD73 expression
UBE2M *538T>G
AQP1 expression
APC mutation + BRCA2 mutation
NRG3 deletion
miR-4490 deletion
miR-1261 deletion
miR-4465 deletion
miR-1269 deletion
CES1 rs9921399T>C
HLA-A*02
CEACAM5 positive
SMO mutation
PIK3CA E546
PIK3CA E545K
PIK3CA H1047R
PIK3CA mutation
PIK3CA E545
MSI-H/dMMR + TMB-L
MSI-H/dMMR + PMS2 deletion
MET overexpression
MSH2 mutation
MSI-H/dMMR + HER-2 mutation
HER-2 amplification + KRAS G12D
PIK3CA H1047
PIK3CA E542
NTRK1 G667C
NTRK1 G595R
PIK3CA V955G
PD-1 positive
PTGS2 mutation
MET expression
PIK3CA P449T
FBXW7 mutation
FGFR2 amplification
FBXW7 R505C
PIK3CA mutation + KRAS mutation
PIK3CA wild-type + KRAS wild-type
VEGFA overexpression
PIK3CA K966E
FBXW7 overexpression
CIC deletion
HIF1A overexpression
PIK3CA K944N
MSH6 mutation
HIF1A underexpression
EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification
PIK3CA E542K
ERAP1 rs2287987
PIK3CA mutation + RAS wild-type
RAS mutation
DDR
LIFR D578N
IRS2 amplification + KRAS mutation
IGF1R overexpression + KRAS mutation
IR overexpression + KRAS mutation
TIMP2 overexpression
miR-126 overexpression
PTEN mutation + MSI-H/dMMR
TERT mutation + BRAF V600E
miR-7-5p overexpression
STING mutation
LMNA-NTRK1 G667C
miR-10a-5p overexpression
ERCC1 promoter methylation
PTPA rs2541164
TAPBP rs3106191
HLA-DOB rs11244
NR4A1 overexpression
ERN1 rs16947383
XBP1 rs2239815
ABCG2 expression
ABCB1 expression
TROP2 expression
PERK rs6731022
HLA-DMB rs10751
PD-L1 expression + CD47 expression
CD47 expression + EPCAM expression
PAI1 expression
BCAT1 expression
KLF4 A472D
KLF4 overexpression
TPM3-NTRK1 fusion
PTPN1 overexpression
ABCG2 overexpression
PRSS1 overexpression
ERCC1 overexpression
SORT1 expression
MCL1 overexpression
CD8 positive
EZR overexpression + BRAF V600E
CXCL10 overexpression
MTAP deletion
CD133 expression
AMHR2 expression
IGF1R overexpression
SRC overexpression + BRAF V600E
LGALS4 expression
CDH1 expression
FXYD3 expression
IGF2BP1 overexpression
HMGA2 expression
TGM2 expression
TP53 mutation + KRAS mutation
FNDC1 overexpression
EGFR overexpression + BRAF V600E
KRAS mutation + TP53 wild-type
MYC amplification
CDC42 elevation
EGFR overexpression + BRAF mutation
EGFR mutation + BRAF V600E
XPO1 R749Q
MUC16 elevation
ETV5 overexpression
CRIPTO expression
ADAM9 expression
APC mutation
BRAF V600E + PIK3CA mutation
IKBKE mutation
EWSR1 mutation
ETV5 mutation
TCF7L2 mutation
RAS wild-type + BRAF wild-type + MAP2K1 N57K
ADAM17 overexpression
MALAT1 overexpression
miR-324-3p underexpression
XRCC2 mutation
DKK4 overexpression
ALPP expression
TPM3-NTRK1 G595R
ETV6-NTRK3 G623R
AMER1 mutation
STAG2 mutation
NOTCH1 mutation
FANCA mutation
PIK3CA exon 20 mutation + HR positive
ABCB1 overexpression
IL2RA expression
SIRT6 underexpression
FGFR1 amplification
GSTA2 overexpression
LCN2 overexpression
LAMP1 expression
YKL-40 overexpression
GOPC-ROS1 fusion + KRAS Q61H
CD133 rs3130
SORT1 positive
XRCC2 deletion
FGFR4 expression
PRKCH fusion
PRKCH-SPTB fusion
PRKCH-VWA2 fusion
HIF1A-PRKCH fusion
ABCC1 rs17501011G>A
RAS wild-type + HGF elevation
BRAF wild-type + HGF elevation
PD-L2 overexpression
PLK1 overexpression
BRAF V600E + KRAS G12R
PODXL overexpression
MSH3 mutation
MSI-H/dMMR + MLH1 deletion + PMS2 deletion
STRN-ALK fusion + KRAS G13D
MAP2K1 mutation + RAS wild-type
MAP2K1 K57T
RPL22L1 overexpression
MAP2K1 V211D
MAP2K1 G128D + KRAS mutation
KRAS G13D + BRAF mutation
MAP2K1 V211D + BRAF mutation
ARID1A deletion
REV1 2108G > A
KRAS mutation + EGFR amplification
PIK3CA mutation + BRAF wild-type
POLR1D expression
IGF1R I668N
IGF1R E1218K
POLR1D amplification
LRIG1 T152T
LRIG2 S697L
PDGFRA T301T
LRIG3 V812M
NCOR1 mutation + MSI-L/dMMR
ERCC6 overexpression
miR-375 expression
miR-199a-5p expression
JAG1 expression
MAP2K1 mutation + BRAF wild-type
MSI-H/dMMR + MLH1 deletion
ROS1 amplification
MAP2K1 F53L
MSI-H/dMMR + HLA-DPB1 overexpression
TACC3 expression
TOP2A overexpression
LMNA-NTRK1 rearrangement
ARAF Q489L
TOP2A amplification
GPR52 mutation
IGFBP6 underexpression
IR overexpression
MYC mutation
EPHA2 overexpression + EGFR overexpression
FOXO3 rs12212067
MSI-H/dMMR + TP53 mutation
BRCA2 mutation + TP53 mutation
ARID1A mutation
TP53BP1 mutation
DDX5 overexpression
AXL overexpression
NOTCH1 amplification
NICD expression
CLDN18.2 expression
FGFR4 overexpression
DKK1 overexpression
AXL expression
HK1 overexpression
SLC6A19 rs7736074
EGFR mutation + KRAS mutation
SLC6A19 rs4975596
PTP4A3 overexpression
MLH1 deletion
EPHB4 overexpression